These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 29117640)
1. Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro. Xu RA; Wen J; Tang P; Wang C; Xie S; Zhang BW; Zhou Q; Cai JP; Hu GX Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):383-387. PubMed ID: 29117640 [TBL] [Abstract][Full Text] [Related]
2. Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro. Li YH; Lin QM; Pang NH; Zhang XD; Huang HL; Cai JP; Hu GX Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):337-344. PubMed ID: 31058459 [TBL] [Abstract][Full Text] [Related]
3. Functional assessment of Fang P; Tang PF; Xu RA; Zheng X; Wen J; Bao SS; Cai JP; Hu GX Drug Des Devel Ther; 2017; 11():3503-3510. PubMed ID: 29263648 [TBL] [Abstract][Full Text] [Related]
4. Functional characterization of 27 CYP3A4 variants on macitentan metabolism in vitro. Li YH; Lu XR; Lin QM; Huang HL; Liang XL; Cai JP; Cui J; Hu GX J Pharm Pharmacol; 2019 Nov; 71(11):1677-1683. PubMed ID: 31441067 [TBL] [Abstract][Full Text] [Related]
5. Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism. Tang PF; Zheng X; Hu XX; Yang CC; Chen Z; Qian JC; Cai JP; Hu GX Drug Des Devel Ther; 2020; 14():5129-5141. PubMed ID: 33262574 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Recombinant CYP3A4 Variants on the Metabolism of Oxycodone In Vitro. Cai Y; Lin Q; Jin Z; Xia F; Ye Y; Xia Y; Papadimos TJ; Wang Q; Hu G; Cai J; Chen L Chem Res Toxicol; 2021 Jan; 34(1):103-109. PubMed ID: 33393779 [TBL] [Abstract][Full Text] [Related]
7. Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro. Han M; Zhang X; Ye Z; Wang J; Qian J; Hu G; Cai J Chem Biol Interact; 2021 Dec; 350():109700. PubMed ID: 34648813 [TBL] [Abstract][Full Text] [Related]
8. Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro. Han M; Qian J; Ye Z; Xu R; Chen D; Xie S; Cai J; Hu G Chem Biol Interact; 2021 Aug; 345():109559. PubMed ID: 34153224 [TBL] [Abstract][Full Text] [Related]
9. Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism. Chen B; Zhang XD; Wen J; Zhang B; Chen D; Wang S; Cai JP; Hu GX Chem Res Toxicol; 2020 Jan; 33(1):172-180. PubMed ID: 31560202 [TBL] [Abstract][Full Text] [Related]
10. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. van Hoppe S; Rood JJM; Buil L; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH Mol Pharm; 2018 Nov; 15(11):5124-5134. PubMed ID: 30247919 [TBL] [Abstract][Full Text] [Related]
11. Possible influence of some foods on the metabolism of ibrutinib. Kronabel D Clin Lab; 2015; 61(3-4):443-4. PubMed ID: 25975016 [TBL] [Abstract][Full Text] [Related]
12. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092 [TBL] [Abstract][Full Text] [Related]
13. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes. Han SY; Zhao HY; Zhou N; Zhou F; Li PP J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377 [TBL] [Abstract][Full Text] [Related]
14. Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro. Xie SL; Zhu X; Gao N; Lin Q; Chen C; Yang YJ; Cai JP; Hu GX; Xu RA Food Chem Toxicol; 2023 Nov; 181():114101. PubMed ID: 37863381 [TBL] [Abstract][Full Text] [Related]
15. Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro. Yang CC; Zheng X; Liu TH; Wang CC; Tang PF; Chen Z; Zhang BW; Fang P; Hu GX; Cai JP Xenobiotica; 2019 Jan; 49(1):120-126. PubMed ID: 29394111 [TBL] [Abstract][Full Text] [Related]
16. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone. Miyazaki M; Nakamura K; Fujita Y; Guengerich FP; Horiuchi R; Yamamoto K Drug Metab Dispos; 2008 Nov; 36(11):2287-91. PubMed ID: 18669585 [TBL] [Abstract][Full Text] [Related]
17. Functional gene variants of CYP3A4. Werk AN; Cascorbi I Clin Pharmacol Ther; 2014 Sep; 96(3):340-8. PubMed ID: 24926778 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants. Akiyoshi T; Saito T; Murase S; Miyazaki M; Murayama N; Yamazaki H; Guengerich FP; Nakamura K; Yamamoto K; Ohtani H Drug Metab Dispos; 2011 Apr; 39(4):724-8. PubMed ID: 21212239 [TBL] [Abstract][Full Text] [Related]
19. Identification and Functional Assessment of Eight Qi Y; Yang H; Wang S; Zou L; Zhao F; Zhang Q; Hong Y; Luo Q; Zhou Q; Geng P; Chen H; Ji F; Cai J; Dai D Drug Metab Dispos; 2024 Feb; 52(3):218-227. PubMed ID: 38195522 [TBL] [Abstract][Full Text] [Related]
20. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Brandes LJ; Queen GM; LaBella FS Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]